Pyxis Oncology, INC Form 4 insider transactions

Director Darren S. Cline reports changes in beneficial ownership of Pyxis Oncology, Inc. stock, including the acquisition of restricted stock units and disposal of common stock.

Director Freda Lewis-Hall reports acquisition of 35,219 restricted stock units in Pyxis Oncology, Inc.

Director Jakob Dupont acquired 38,741 shares of Pyxis Oncology common stock on March 26, 2024.

Director Rachel Humphrey reports acquiring 38,741 shares of Pyxis Oncology stock and disposing of 96,805 shares on March 26, 2024.

Thomas Civik, a director at Pyxis Oncology, acquired stock options for 44,024 shares of common stock at an exercise price of $3.83 on March 26, 2024.

Jitendra Wadhane, SVP, Chief Accounting Officer of Pyxis Oncology, reports acquiring and disposing of common stock on March 26, 2024.

Director Santhosh Palani of Pyxis Oncology, Inc. acquired stock options for 69,760 shares on March 12, 2024.